fda approved tirzepatide The New FDA-Approved Game Changer

Tirzepatide (Mounjaro, Zepbound) is technically a dual GIP/GLP-1 receptor agonist, hitting two incretin receptors instead of one, which explains its superior weight loss outcomes in clinical trials

Although the same active ingredient in Ozempic is found in several weight loss medications, it's essential to understand that Ozempic itself is not FDA-approved for weight loss

Although semaglutide (Ozempic/Wegovy) has largely overtaken liraglutide in clinical preference due to its weekly dosing and greater weight loss efficacy, liraglutide retains several advantages: it has over 15 years of post-marketing safety data, cardiovascular outcome data from the landmark LEADER trial, and pediatric approvals for both diabetes and obesity

Inia et al

However, somehow, it can be associated with some disadvantages